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1. INTRODUCTION {#dom13575-sec-0005}
===============

Aging populations and modern lifestyles have been increasingly associated with higher levels of dyslipidaemia and impairment of glucose metabolism in diseases such as type 2 diabetes around the world. Each of these conditions is a known risk factor for cardiovascular disease (CVD), and the risk of a cardiovascular (CV) event is even higher in patients with both conditions.[1](#dom13575-bib-0001){ref-type="ref"}, [2](#dom13575-bib-0002){ref-type="ref"}, [3](#dom13575-bib-0003){ref-type="ref"} Among patients with diabetes, the CV risk is known to be further increased in patients whose diabetes is complicated by retinopathy; such patients are recognized to be at very high risk for CVD.[4](#dom13575-bib-0004){ref-type="ref"}, [5](#dom13575-bib-0005){ref-type="ref"}

The EMPATHY study is the first to assess the benefits of intensive statin therapy in patients with type 2 diabetes with hyperlipidaemia and diabetic retinopathy in a primary prevention setting, and also the first large‐scale clinical study to evaluate the effectiveness of the treat‐to‐target approach. The study compared the benefits of intensive and standard statin therapy for reducing a composite of CV events or deaths from CV events (the primary endpoint). Analysis of the intention‐to‐treat (ITT) population showed that lipid‐lowering therapy targeting LDL cholesterol \<1.81 mmol/L (\<70 mg/dL) did not have a more beneficial effect on the primary endpoint than therapy targeting LDL cholesterol ≥2.59 to \<3.10 mmol/L (≥100 to \<120 mg/dL) (hazard ratio \[HR\] 0.84, 95% confidence interval \[CI\] 0.67‐1.07; *P* = 0.15).[6](#dom13575-bib-0006){ref-type="ref"} These findings appeared to contradict earlier findings that showed benefits of lower LDL cholesterol in patients with diabetes.[7](#dom13575-bib-0007){ref-type="ref"}, [8](#dom13575-bib-0008){ref-type="ref"}, [9](#dom13575-bib-0009){ref-type="ref"} Notably, however, the LDL cholesterol target in the EMPATHY study was achieved by fewer than half of the patients in either group. In addition, a large percentage of patients on standard therapy in the original study (targeting ≥2.59 to \<3.10 mmol/L) actually achieved LDL cholesterol levels below the target range (Figure [1](#dom13575-fig-0001){ref-type="fig"}). These factors may have contributed to masking the efficacy of the intensive therapy.

![Distribution of LDL cholesterol in the intensive and standard therapy groups in the original study](DOM-21-791-g001){#dom13575-fig-0001}

To further investigate the efficacy of intensive therapy, we conducted additional exploratory analyses of between‐group comparisons. Although previous large‐scale clinical studies of statins have included exploratory (post hoc) analyses stratified by lipid levels achieved, in all cases, these sub‐analyses were for dose comparison studies. More importantly, none of the studies assessed whether the patients achieved prespecified goals for LDL cholesterol levels.[10](#dom13575-bib-0010){ref-type="ref"}, [11](#dom13575-bib-0011){ref-type="ref"}

We limited our sub‐analyses to those patients whose LDL cholesterol levels were within the targeted range, in order to better assess the effects of the treat‐to‐target approach in these patient populations. Our hypothesis was that intensive therapy in patients who achieved their target (LDL cholesterol \<1.81 mmol/L) would be superior to standard therapy (LDL cholesterol target ≥2.59 to \<3.10 mmol/L) in reducing the incidence of composite CV events.

2. MATERIALS AND METHODS {#dom13575-sec-0006}
========================

2.1. Study design {#dom13575-sec-0007}
-----------------

The EMPATHY study was conducted to determine whether intensive lipid‐lowering therapy is superior to standard therapy in reducing the incidence of CV events or death from CV events in patients with type 2 diabetes complicated by hyperlipidaemia and diabetic retinopathy and without a history of CVD.[6](#dom13575-bib-0006){ref-type="ref"}, [12](#dom13575-bib-0012){ref-type="ref"} The study used a multicentre, prospective, randomized, open‐label, blinded endpoint (PROBE) design. It was conducted in Japan in accordance with the Declaration of Helsinki and Japanese ethical guidelines for clinical studies. The protocol was reviewed and approved by the institutional review board of each participating centre. The study was registered with the University Hospital Medical Information clinical trials registry (UMIN000003486).

The sub‐analysis design was based on the results of the primary analysis of the EMPATHY study, in which patients were initially treated to ≥2.59 to \<3.10 mmol/L (run‐in period) and were then randomized (1:1) to intensive therapy targeting LDL cholesterol \<1.81 mmol/L or standard therapy targeting ≥2.59 to \<3.10 mmol/L (treatment period). The primary endpoint was a composite of the incidence of CV events (cardiac, cerebral, renal and vascular events) and death from CV events, compared between the two groups.

2.2. Patients {#dom13575-sec-0008}
-------------

This sub‐analysis was performed on data collected from patients in the EMPATHY study who achieved mean LDL cholesterol levels of \<1.81 mmol/L in the intensive therapy group in the original study (the intensive group) and ≥2.59 to \<3.10 mmol/L in the standard therapy group in the original study (the standard group). The mean LDL cholesterol for each patient was defined as the mean value of measurements obtained at scheduled visits, starting 6 months after randomization to the intensive therapy group or the standard therapy group in the original study, and continuing to the final visit for those who developed no events or to the nearest day before onset for those who developed any events.

2.3. Procedures {#dom13575-sec-0009}
---------------

Analysis included all patients who had at least one scheduled visit during the period starting 6 months after randomization. For reference, in comparison to these mean values, additional analysis was performed on data collected from patients who showed the target LDL cholesterol level at their last visit. The last visit was defined to be the nearest day before onset of an event for patients who developed any events, or the date of the final visit for patients who did not develop any events during the scheduled visits, starting 6 months after randomization to a treatment group.

2.4. Outcomes {#dom13575-sec-0010}
-------------

In the EMPATHY study, the primary outcome was the composite incidence of CV events, including cardiac, cerebral, renal and vascular events, or death associated with CV events. The secondary outcomes included death from any cause; individual incidence of the events defined as CV events for the primary endpoint; incidence of stroke; change in laboratory variables related to chronic kidney disease; and safety. Primary and secondary endpoints were adjudicated by an event evaluation committee whose members were unaware of the treatment allocation. In this sub‐analysis, we analysed only the primary outcome and safety because of the small number of CV events.

2.5. Statistical analysis {#dom13575-sec-0011}
-------------------------

A Cox proportional hazards model was used to estimate the hazard ratios (HRs) and 95% confidence intervals (CIs) for the incidence of the primary endpoint in patients who achieved target LDL cholesterol levels in the intensive and standard groups. Because this additional analysis was performed in a sub‐group of patients, a Cox proportional hazards model was applied, with study group and baseline influencing factors as explanatory variables, to adjust for these factors.

A stepwise method was used with the Cox proportional hazards model in the full analysis set (ITT population) to select influencing factors; the primary endpoint was the objective variable, and prognostic factors were the explanatory variables. In this analysis, 15 potential prognostic factors were evaluated: gender, age, body mass index, compliance with lipid‐lowering agents (including statins) from enrolment, smoking status (current smoker, past smoker, non‐smoker), family history of coronary artery disease, family history of cerebrovascular disease, duration of diabetes, presence or absence of diabetic nephropathy, presence or absence of diabetic neuropathy, presence or absence of hypertension, funduscopic findings at enrolment (simple retinopathy, pre‐proliferative retinopathy, proliferative retinopathy), glycated haemoglobin (HbA1c) at informed consent, LDL cholesterol at randomization, and estimated glomerular filtration rate (eGFR) at enrolment (\<60, ≥60 mL/min/1.73 m^2^).

3. RESULTS {#dom13575-sec-0012}
==========

3.1. Study participants {#dom13575-sec-0013}
-----------------------

Of the 5144 patients randomized to the intensive and standard therapy groups in the EMPATHY study, a total of 1909 were included in this sub‐analysis (703 in the intensive group and 1206 in the standard group). A total of 70 patients (25 in the intensive group and 45 in the standard group) had only one scheduled visit at least 6 months after randomization.

3.2. Baseline characteristics {#dom13575-sec-0014}
-----------------------------

Some of the demographic characteristics of the patients in both groups at baseline were similar (age, family history of coronary artery disease and/or cerebrovascular disease, presence of neuropathy and/or nephropathy, severity of retinopathy, HbA1c levels and eGFR), while other characteristics differed between the groups (Table [1](#dom13575-tbl-0001){ref-type="table"}). In comparison to the standard therapy group, a higher proportion of patients in the intensive therapy group was male (51.9% vs. 43.5%), received no lipid‐lowering treatment before study enrolment (54.9% vs. 39.1%), were current smokers (19.3% vs. 16.9%), and had hypertension at enrolment (75.7% vs. 70.6%). Other differences between the two groups included higher mean BMI in the intensive group, and longer duration of diabetes and higher mean LDL cholesterol level at enrolment in the standard group.

###### 

Baseline demographic characteristics (potential prognostic factors): for patients achieving LDL cholesterol target in mean value

                                                                   Intensive group   Standard group   
  ---------------------------------------------------------------- ----------------- ---------------- --------------------------------------------------
  Male                                                             365 (51.9)        525 (43.5)       \<0.001[\*](#dom13575-note-0004){ref-type="fn"}
  Age, years[a](#dom13575-note-0006){ref-type="fn"}                62.7 (10.8)       63.6 (10.1)      0.23[^†^](#dom13575-note-0005){ref-type="fn"}
  Body mass index, kg/m^2^                                         26.2 (4.2)        25.5 (4.2)       \<0.001[^†^](#dom13575-note-0005){ref-type="fn"}
  Lipid‐lowering agents[b](#dom13575-note-0007){ref-type="fn"}                                        
  None                                                             386 (54.9)        472 (39.1)       \<0.001[\*](#dom13575-note-0004){ref-type="fn"}
  1 drug                                                           316 (45.0)        733 (60.8)       
  ≥2 drugs                                                         1 (0.1)           1 (0.1)          
  Statins[b](#dom13575-note-0007){ref-type="fn"}                                                      \<0.001[\*](#dom13575-note-0004){ref-type="fn"}
  No                                                               428 (60.9)        511 (42.4)       
  Yes                                                              275 (39.1)        695 (57.6)       
  Smoking[c](#dom13575-note-0008){ref-type="fn"}                   136 (19.3)        204 (16.9)       0.01[\*](#dom13575-note-0004){ref-type="fn"}
  Family history                                                                                      
  Coronary artery disease                                          86 (12.2)         165 (13.7)       0.37[\*](#dom13575-note-0004){ref-type="fn"}
  Cerebrovascular disease                                          146 (20.8)        261 (21.6)       0.65[\*](#dom13575-note-0004){ref-type="fn"}
  Duration of diabetes, years                                      12.3 (8.3)        13.4 (9.1)       0.02[^†^](#dom13575-note-0005){ref-type="fn"}
  Diabetic complications                                                                              
  Neuropathy                                                       217 (30.9)        382 (31.7)       0.71[\*](#dom13575-note-0004){ref-type="fn"}
  Nephropathy                                                      385 (54.8)        614 (50.9)       0.10[\*](#dom13575-note-0004){ref-type="fn"}
  Hypertension                                                     532 (75.7)        852 (70.6)       0.02[\*](#dom13575-note-0004){ref-type="fn"}
  Funduscopy[d](#dom13575-note-0009){ref-type="fn"}                                                   
  Simple retinopathy                                               454 (64.6)        785 (65.1)       0.99[\*](#dom13575-note-0004){ref-type="fn"}
  Preproliferative retinopathy                                     141 (20.1)        243 (20.1)       
  Proliferative retinopathy                                        103 (14.7)        170 (14.1)       
  Other[e](#dom13575-note-0010){ref-type="fn"}                     3 (0.4)           5 (0.4)          
  HbA1c, %[a](#dom13575-note-0006){ref-type="fn"}                  7.71 (1.20)       7.71 (1.19)      0.91[^†^](#dom13575-note-0005){ref-type="fn"}
  LDL cholesterol, mmol/L[f](#dom13575-note-0011){ref-type="fn"}   2.42 (0.62)       2.79 (0.61)      \<0.001[^†^](#dom13575-note-0005){ref-type="fn"}
  eGFR, mL/min/1.73 m^2^                                           75.1 (21.7)       74.6 (19.6)      0.81[^†^](#dom13575-note-0005){ref-type="fn"}

Abbreviations: HbA1c, glycated haemoglobin; eGFR, estimated glomerular filtration rate.

Data are mean (SD) or n (%).

\*The χ^2^ test without Yates\' correction.

^†^Wilcoxon rank sum test.

Values obtained at the time of consent.

Values obtained at provisional enrolment.

Not including past smokers.

Diagnosed by ophthalmologists based on the modified Davis classification.

Includes five patients who had a history of laser therapy but no funduscopic findings at enrolment. The remaining three patients were found to be retinopathy‐negative after enrolment.

Values were calculated using the Friedewald equation; LDL cholesterol = total cholesterol − \[HDL cholesterol + triglycerides/5\].

The demographic characteristics of the patients who were at their target LDL cholesterol level at the last visit were similar to those who were at their mean target LDL cholesterol level, with the exception of nephropathy (Table [S1](#dom13575-supitem-0001){ref-type="supplementary-material"}, Appendix [S1](#dom13575-supitem-0001){ref-type="supplementary-material"}).

The proportion of patients using atorvastatin, rosuvastatin or pitavastatin was about the same in the two groups at baseline (48.2% in the intensive group and 53.1% in the standard group), and the proportion using pravastatin, fluvastatin or simvastatin was 51.2% and 46.7%, respectively. At the end of the study, the proportion of atorvastatin, rosuvastatin or pitavastatin users remained nearly unchanged in the standard group (50.9%), but had risen to 98.2% in the intensive group. Dose levels at baseline were similar in the intensive and standard groups for all statins. In the intensive group, the dose increased for all statin types over the course of the study. The doses did not change for the standard group (Table [S2](#dom13575-supitem-0001){ref-type="supplementary-material"}, Appendix [S1](#dom13575-supitem-0001){ref-type="supplementary-material"}). It should be noted that the statin dose for "intensive" therapy in Japan is lower than in the United States and Europe.

3.3. Laboratory values {#dom13575-sec-0015}
----------------------

The changes in levels of LDL cholesterol, total cholesterol, HDL cholesterol and triglycerides in the sub‐analysis are shown in Figure [2](#dom13575-fig-0002){ref-type="fig"}. In the intensive group, the mean level of LDL cholesterol decreased significantly from baseline (2.42 ± 0.62 mmol/L) to the first measurement at 6 months (1.72 ± 0.36 mmol/L) and then remained at this level or lower (1.54 ± 0.30 mmol/L at 36 months) to 60 months after the start of treatment (1.46 ± 0.42 mmol/L). In the standard group, the LDL cholesterol level after 6 months of treatment was slightly higher (2.83 ± 0.45 mmol/L) than the baseline level (2.79 ± 0.61 mmol/L) and remained at or near that level (2.77 ± 0.46 mmol/L at 36 months) throughout the course of the study to 60 months after the start of treatment, when it dropped slightly to near‐baseline level (2.78 ± 0.58 mmol/L). Total cholesterol showed a similar pattern to LDL cholesterol in both groups. Triglyceride levels were slightly higher in the intensive group at baseline, but that gap diminished somewhat after the start of the study. HDL cholesterol remained substantially unchanged throughout the study in both groups.

![Changes in lipid variables over time. Data are mean and SD values. The black line shows findings for the intensive group and the gray line shows findings for the standard group. \**P* \< 0.05, calculated using a mixed model repeated measures approach. The model included group, observation time point, and interaction between group and observation time point as fixed effects. TC, total cholesterol; TG, triglycerides](DOM-21-791-g002){#dom13575-fig-0002}

No changes were noted for either group during the study in blood pressure, HbA1c, creatinine or creatine kinase; however, in the intensive group, high‐sensitivity C‐reactive protein (hsCRP) levels were significantly reduced at all time points except 60 months, and there was a significant difference between the groups in hsCRP (Table [S3](#dom13575-supitem-0001){ref-type="supplementary-material"}, Appendix [S1](#dom13575-supitem-0001){ref-type="supplementary-material"}).

3.4. Efficacy endpoints {#dom13575-sec-0016}
-----------------------

Since stepwise variable selection showed that eight factors were statistically related to the primary outcome among the 15 potential prognostic factors, the analysis was adjusted for these variables: gender; smoking status (current smoker, past smoker, non‐smoker); presence or absence of diabetic nephropathy, neuropathy, or hypertension; funduscopic findings at enrolment; HbA1c at informed consent; and eGFR at enrolment (\<60, ≥60 mL/min/1.73 m^2^). Baseline LDL cholesterol was not found to be a prognostic factor. We adjusted for these eight prognostic factors to estimate HRs and 95% CIs for the incidence of CV events (the primary endpoint of the EMPATHY study).

In this sub‐analysis, a significantly smaller proportion of patients in the intensive group (18/703 patients) experienced CV events or death associated with CV events than in the standard group (56/1206 patients; HR 0.48, 95% CI 0.28‐0.82; *P* = 0.007 \[Figure [3](#dom13575-fig-0003){ref-type="fig"} and Table [S4](#dom13575-supitem-0001){ref-type="supplementary-material"}, Appendix [S1](#dom13575-supitem-0001){ref-type="supplementary-material"}\]). This difference between the groups started at \~12 months after randomization. These findings remained unchanged even if baseline LDL cholesterol was added as a ninth prognostic factor (data not shown).

![Cumulative event curve for the primary endpoint in the intensive and standard groups (patients achieving LDL cholesterol target, mean value). Hazard ratio (HR), 95% confidence interval (CI) and *P* value were estimated using a stratified Cox proportional hazards model, with gender (male, female), smoking status, presence or absence of diabetic nephropathy, presence or absence of diabetic neuropathy, presence or absence of hypertension, funduscopic findings, and baseline glycated haemoglobin (\<8.4, ≥8.4%) and estimated glomerular filtration rate (\<60, ≥60 \[mL/min/1.73 m^2^\]) as covariates](DOM-21-791-g003){#dom13575-fig-0003}

In the above sub‐analysis, we used mean LDL cholesterol values to determine whether each patient achieved the target range. We then repeated our analysis using LDL cholesterol values at the last visit. In this analysis we also noted a significant difference in the primary endpoint between the intensive group and the standard group (HR 0.43, 95% CI 0.27‐0.68; *P* \< 0.001 \[Figure [4](#dom13575-fig-0004){ref-type="fig"}\]).

![Cumulative event curve for the primary endpoint in the intensive and standard groups (patients achieving LDL cholesterol target at the last visit). Hazard ratio (HR), 95% confidence interval (CI) and *P* value are estimated using a Cox proportional hazards model with gender (male, female), smoking status, presence or absence of diabetic nephropathy, presence or absence of diabetic neuropathy, presence or absence of hypertension, funduscopic findings, and baseline glycated haemoglobin (\<8.4, ≥8.4%) and estimated glomerular filtration rate (\< 60, ≥60 mL/min/1.73 m^2^) as covariates](DOM-21-791-g004){#dom13575-fig-0004}

3.5. Safety {#dom13575-sec-0017}
-----------

The safety endpoints examined in this analysis were adverse events (AEs), serious AEs, adverse drug reactions (ADRs) and serious ADRs. There was no significant difference in the incidence rates for each of these endpoints between the two groups. The major AEs were hepatobiliary disorders, renal and urinary disorders, rhabdomyolysis, myopathy and cancer (Table [S5](#dom13575-supitem-0001){ref-type="supplementary-material"}, Appendix [S1](#dom13575-supitem-0001){ref-type="supplementary-material"}). Overall, the occurrence of these events in the two groups was similar except for renal and urinary disorders, which were more common in the standard group (9.2%) than in the intensive group (5.7%).

4. DISCUSSION {#dom13575-sec-0018}
=============

The EMPATHY study assessed the benefits of intensive statin monotherapy for lipid management in patients with type 2 diabetes complicated by hypercholesterolaemia and diabetic retinopathy in a primary prevention setting. The study also evaluated the appropriateness of the treat‐to‐target approach in this patient population. Results from the EMPATHY study showed that intensive lipid‐lowering therapy targeting \<1.81 mmol/L of LDL cholesterol was no more effective in reducing a composite of incidence of CV events or death from CV events than standard therapy targeting ≥2.59 to \<3.10 mmol/L (HR 0.84, 95% CI 0.67‐1.07)[6](#dom13575-bib-0006){ref-type="ref"}; however, the ITT method may lead to underestimation of intergroup differences in efficacy in situations where the treatment goals have not been properly achieved. In the present study, in particular, fewer than half of the patients in each group had LDL cholesterol levels within their target range, and nearly half in the standard group had LDL cholesterol levels below the target.

Our planned between‐group difference in LDL cholesterol was \~1.03 mmol/L (\~40 mg/dL) (\<1.81 mmol/L for the intensive therapy group compared with \~2.84 mmol/L (\~110 mg/dL) for the standard therapy group) in the original study, with a predicted HR of 0.65; however, after 3 years of treatment, the actual LDL cholesterol difference was 0.72 mmol/L (1.98 vs. 2.69 mmol/L). We hypothesized that the smaller‐than‐expected difference may have been attributable, at least in part, to the unexpectedly low number of patients who achieved their LDL target. Our exploratory post hoc analyses were designed to investigate this hypothesis by comparing findings between patients whose LDL cholesterol was within the target range for their group.

The sub‐analysis involved differences in some prognostic factors between the patient group meeting their target LDL cholesterol levels of \<1.81mmol/L under intensive therapy and the patient group meeting their LDL cholesterol levels of 2.59 to 3.10 mmol/L under standard therapy. We adjusted for eight factors that had been identified as potentially affecting the primary endpoint: gender (male, female); smoking status; presence or absence of diabetic nephropathy; presence or absence of diabetic neuropathy; presence or absence of hypertension; funduscopic findings; baseline HbA1c; and eGFR. We also found some significant intergroup differences for body mass index, use of lipid‐lowering agents, use of statins, duration of diabetes, and baseline LDL cholesterol level; however, because they did not affect the primary endpoints in this study, we did not adjust for those factors. After adjusting for the eight selected prognostic factors, the results of the analysis showed that the intensive lipid‐lowering therapy targeting \<1.81 mmol/L LDL cholesterol significantly reduced the primary endpoint (the composite of incidence of CV events or death from CV events). Because of the low number of events (74), in this analysis we limited the number of factors, using a stepwise method for adjustment in the analytical model. We did this to avoid potentially non‐reproducible and unstable results. For further confirmation, we also performed an analysis with all variables included; similar results were obtained (HR 0.51; 95% CI 0.29‐0.89; *P* \< 0.05 \[Table [S6](#dom13575-supitem-0001){ref-type="supplementary-material"}, Appendix [S1](#dom13575-supitem-0001){ref-type="supplementary-material"}\]). Safety events occurred at approximately the same rate in the two groups.

We used mean values for LDL cholesterol in patients who achieved their target levels because we thought it was important to ensure that patients were exposed to a specific concentration of LDL cholesterol for a certain period of time. Our results, although exploratory, suggest that achieving a target of \<1.81 mmol/L LDL cholesterol lowers the risk of CV events significantly more than achieving a target of 2.59 to 3.10 mmol/L. For reference, we have also provided a summary of our findings for the proportion of patients who achieved their target LDL cholesterol level at the last visit. Results were similar to those based on mean values.

In the main results paper, we performed post hoc analysis, which involved classifying patient data into four subcategories (mean LDL cholesterol \<1.81, 1.81 to \<2.59, 2.59 to \<3.10, and ≥3.10 mmol/L during the study). That analysis tended to show event prevention at lower LDL cholesterol values in both the intensive and standard therapy groups in the original study[6](#dom13575-bib-0006){ref-type="ref"}; the results of the present sub‐analysis are consistent with those findings. This fact supports the reliability of our sub‐analysis. Although exploratory, we believe that these findings could meaningfully impact lipid management in clinical practice for the primary prevention of CV events in patients with type 2 diabetes with hyperlipidaemia and diabetic retinopathy.

Previous large‐scale clinical studies of statins have also used LDL cholesterol levels as a basis for post hoc sub‐analyses,[8](#dom13575-bib-0008){ref-type="ref"}, [9](#dom13575-bib-0009){ref-type="ref"}, [10](#dom13575-bib-0010){ref-type="ref"}, [11](#dom13575-bib-0011){ref-type="ref"} and usefulness was demonstrated in groups achieving lower target levels; however, all of these sub‐analyses were in dose comparison studies, and none assessed whether patients had achieved their target LDL cholesterol levels. To the best of our knowledge, no other analyses have been reported that show the effect of specified target LDL cholesterol levels using statin monotherapy on the occurrence of CV events or CV‐related deaths. Although this was an exploratory analysis, our data are valuable when assessing the importance of the treat‐to‐target approach in lipid management.

In the ITT analysis for the EMPATHY study, the difference in LDL cholesterol between the two groups was 0.72 mmol/L, and the HR for the primary endpoint was 0.84 (95% CI 0.67‐1.07; *P* = 0.15).[6](#dom13575-bib-0006){ref-type="ref"} In this sub‐analysis, LDL cholesterol at 36 months was 1.54 mmol/L in the intensive group and 2.77 mmol/L in the standard group, a difference of 1.23 mmol/L (47.4 mg/dL) between the two groups, and the HR was 0.48 (95% CI 0.28‐0.82; *P* = 0.007). In this sub‐analysis, aggressive treatment with the goal of lowering LDL cholesterol to 1.81 mmol/L was clearly effective in reducing the number of occurrences of the primary endpoint. The actual difference in LDL cholesterol exceeded the planned difference of \~1.03 mmol/L, which meant that the actual HR was also higher than the planned HR of 0.65. The main analysis did not detect a significant difference in primary endpoint occurrence between the two groups. These sub‐analysis findings indicate that we were unable to obtain significant results from the main analysis because of failure to achieve target LDL cholesterol levels.

No major differences were noted between groups in the incidence of AEs or ADRs. It thus appears unlikely that specific safety concerns will occur when intensive statin monotherapy is used to reduce LDL cholesterol below 1.81 mmol/L. We found no marked increase in cerebral haemorrhage in the intensive group (two patients in the intensive group, one patient in the standard group), nor any increase in HbA1c associated with statin use in this study.

These study findings are limited because they are derived from an exploratory analysis which included only those patients whose LDL cholesterol was within the target range for their assigned group: LDL cholesterol \<1.81 mmol/L in the intensive therapy group in the original study and ≥2.59 to \<3.10 mmol/L in the standard therapy group in the original study. In the EMPATHY study, \<50% of patients reached their target LDL cholesterol. This can be attributed in part to the fact that over half of the investigators were general practitioners, rather than lipid specialists. Many Japanese physicians who treat hyperlipidaemia as part of their routine clinical practice are not lipid management experts and are concerned about adverse effects such as intracranial haemorrhage from intensive LDL cholesterol‐lowering. Such concerns may have affected some of the investigators in the present study, making them reluctant to prescribe high‐dose statin therapy even when the protocol stipulated the aggressive target of 1.81 mmol/L. Because of the small number of events, secondary endpoints were not assessed (Table [S4](#dom13575-supitem-0001){ref-type="supplementary-material"}, Appendix [S1](#dom13575-supitem-0001){ref-type="supplementary-material"}). In addition, although we detected and adjusted for eight prognostic factors, there may be additional unmeasured factors or confounding factors that should be considered.

In conclusion, the results from this exploratory post hoc analysis suggest that achievement of LDL cholesterol levels below 1.81 mmol/L is associated with more effective reduction of CV events than levels of 2.59 to 3.10 mmol/L in patients with type 2 diabetes with retinopathy and hyperlipidaemia who are at high coronary risk.[4](#dom13575-bib-0004){ref-type="ref"}, [5](#dom13575-bib-0005){ref-type="ref"} There were no major increases in AEs or ADRs when statin monotherapy was used to reduce LDL cholesterol below 1.81 mmol/L. Our results indicate the importance of targeting LDL cholesterol below 1.81 mmol/L, and then meeting that target consistently, for the reduction of CV events in this high‐risk patient population; however, this analysis was exploratory and must be substantiated in randomized clinical trials. A feasible approach is also needed for achieving these target levels in a clinical setting.
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